Market open

Cidara Therapeutics/$CDTX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Cidara Therapeutics

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Ticker

$CDTX
Trading on

Industry

Biotechnology

Employees

69

CDTX Metrics

BasicAdvanced
$123M
Market cap
-
P/E ratio
-$23.94
EPS
0.99
Beta
-
Dividend rate
$123M
0.99
$24.40
$10.00
37K
3.536
2.911
2.043
3.41
-23.89%
-200.46%
1.971
1.06
1.06
-0.55
44.48%
168.66%
-1.04%
6.21%

What the Analysts think about CDTX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Cidara Therapeutics stock.

CDTX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CDTX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CDTX

$

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cidara Therapeutics stock?

Cidara Therapeutics (CDTX) has a market cap of $123M as of November 22, 2024.

What is the P/E ratio for Cidara Therapeutics stock?

The price to earnings (P/E) ratio for Cidara Therapeutics (CDTX) stock is 0 as of November 22, 2024.

Does Cidara Therapeutics stock pay dividends?

No, Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders as of November 22, 2024.

When is the next Cidara Therapeutics dividend payment date?

Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Cidara Therapeutics?

Cidara Therapeutics (CDTX) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.